Hemorrhagic cerebral complications on the background of therapy with clopidogrel in patients with ischemic stroke with CYP2C19*17 polymorphous carriage: a clinical case

Objective. To demonstrate on a clinical example the importance of conducting pharmacogenetic testing in patients with ischemic stroke receiving clopidogrel order to identify polymorphic carriage CYP2C19*17 (C806T, rs12248560). Materials and methods. A laboratory examination 121 was carried out, polymorphism rs12248560) associated an increase effectiveness clopidogrel, low residual platelet reactivity, increased risk bleeding determined. Carriage markers determined by real-time polymerase chain reaction. Results conclusion. In two (1.7 %), carriers CYP2C19*17, hemorrhagic cerebrovascular complications were detected background clopidogrel. Gastrointestinal bleeding, as well other antiplatelet therapy, are not registered practice